Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe

Detalhes bibliográficos
Autor(a) principal: Santos, Anna Clara Ramos da Silva
Data de Publicação: 2022
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFS
Texto Completo: http://ri.ufs.br/jspui/handle/riufs/16325
Resumo: A new coronavirus from the Coronaviridae family was identified in December 2019 as a cause of complications in the pulmonary pathways in humans, SARS-Cov-2. On February 26, 2020, the first case of infection was confirmed in Brazil, and since then a real war has started to fight the pandemic. This work was the first populationbased seroprevalence study on SARS-CoV-2 infection carried out in Sergipe. In this study we investigated the seroprevalence of antibodies against severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) in the state of Sergipe, Northeastern Brazil, using rapid IgM − IgG antibody test and fluorescence immunoassay during the first wave of the disease. in Brazil from July to August 2020. In order to identify gender and age group with the greatest applicability of rapid tests and evaluate the number of asymptomatic and symptomatic people, as well as the most presented symptoms. Seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2– 11.3) for women and 7.9% (95% CI 6, 8–9.1) for men (p = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20– 59 years (9.3%; 95% CI 8.4-10.3) and ≥60 years (9.0%; 95% CI 7.5-10.8) (p = 0.517). The metropolitan region had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than inland municipalities (8.0%, 95% CI 7.2–8.9) (P <0.001). These findings highlight the importance of serosurveillance in estimating the true impact of the COVID-19 outbreak and thereby providing data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results can be useful as baseline data to track the progress of the COVID-19 outbreak as social restraint initiatives begin to be relaxed in Brazil.
id UFS-2_3677eea3a4e08a09196e959f49cadefd
oai_identifier_str oai:ufs.br:riufs/16325
network_acronym_str UFS-2
network_name_str Repositório Institucional da UFS
repository_id_str
spelling Santos, Anna Clara Ramos da SilvaAraújo, Adriano Antunes de Souza2022-09-21T13:57:14Z2022-09-21T13:57:14Z2022-02-28SANTOS, Anna Clara Ramos da Silva. Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe. 2022. 51 f. Dissertação (Mestrado em Ciências Farmacêuticas) – Universidade Federal de Sergipe, São Cristóvão, 2022.http://ri.ufs.br/jspui/handle/riufs/16325A new coronavirus from the Coronaviridae family was identified in December 2019 as a cause of complications in the pulmonary pathways in humans, SARS-Cov-2. On February 26, 2020, the first case of infection was confirmed in Brazil, and since then a real war has started to fight the pandemic. This work was the first populationbased seroprevalence study on SARS-CoV-2 infection carried out in Sergipe. In this study we investigated the seroprevalence of antibodies against severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) in the state of Sergipe, Northeastern Brazil, using rapid IgM − IgG antibody test and fluorescence immunoassay during the first wave of the disease. in Brazil from July to August 2020. In order to identify gender and age group with the greatest applicability of rapid tests and evaluate the number of asymptomatic and symptomatic people, as well as the most presented symptoms. Seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2– 11.3) for women and 7.9% (95% CI 6, 8–9.1) for men (p = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20– 59 years (9.3%; 95% CI 8.4-10.3) and ≥60 years (9.0%; 95% CI 7.5-10.8) (p = 0.517). The metropolitan region had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than inland municipalities (8.0%, 95% CI 7.2–8.9) (P <0.001). These findings highlight the importance of serosurveillance in estimating the true impact of the COVID-19 outbreak and thereby providing data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results can be useful as baseline data to track the progress of the COVID-19 outbreak as social restraint initiatives begin to be relaxed in Brazil.Um novo coronavírus da família Coronaviridae foi identificado em dezembro de 2019 como um causador de complicações nas vias pulmonares nos seres humanos, o SARS-Cov-2. No dia 26 de fevereiro de 2020 foi confirmado o primeiro caso de infecção no Brasil, e desde então se iniciou uma verdadeira guerra no combate a pandemia. Esse trabalho foi o primeiro estudo de soroprevalência de base populacional sobre a infecção pelo SARS-CoV-2 realizado em Sergipe. Neste estudo investigamos a soroprevalência de anticorpos contra síndrome respiratória aguda grave-coronavírus-2 (SARS-CoV-2) no estado de Sergipe, Nordeste do Brasil, usando teste rápido de anticorpos IgM − IgG e imunoensaio de fluorescência durante a primeira onda da doença no Brasil no período de julho a agosto de 2020. Afim de identificar gênero e faixa etária com a maior aplicabilidade de testes rápidos e avaliar o número de pessoas assintomáticas e sintomáticas, bem como os sintomas mais apresentados. A soroprevalência foi de 9,3% (IC 95% 8,5–10,1), 10,2% (IC 95% 9,2–11,3) para mulheres e 7,9% (IC 95% 6,8–9,1) para homens (p = 0,004). Encontramos um declínio na prevalência de anticorpos SARS-CoV-2 de acordo com a idade, mas as diferenças não foram estatisticamente significativas: 0–19 anos (9,9%; IC 95% 7,8–12,5), 20–59 anos (9,3%; IC 95% 8,4-10,3) e ≥60 anos (9,0%; IC 95% 7,5-10,8) (p = 0,517). A região metropolitana teve uma soroprevalência mais alta (11,7%, IC 95% 10,3–13,2) do que os municípios do inteior (8,0%, IC 95% 7,2–8,9) (P <0,001). Esses achados destacam a importância da sorovigilância para estimar o impacto real do surto de COVID-19 e, assim, fornecer dados para melhor compreender a propagação do vírus, além de fornecer informações para orientar as medidas de permanência em casa e outras políticas. Além disso, esses resultados podem ser úteis como dados básicos para acompanhar o progresso do surto de COVID-19 à medida que iniciativas de restrição social começam a ser flexibilizadas no Brasil.São CristóvãoporCOVID-19Inquéritos epidemiológicosSergipeEpidemiological inquiriesCIENCIAS DA SAUDE::FARMACIADeterminação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisPós-Graduação em Ciências FarmacêuticasUniversidade Federal de Sergipereponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain; charset=utf-81475https://ri.ufs.br/jspui/bitstream/riufs/16325/1/license.txt098cbbf65c2c15e1fb2e49c5d306a44cMD51ORIGINALANNA_CLARA_RAMOS_S_SANTOS.pdfANNA_CLARA_RAMOS_S_SANTOS.pdfapplication/pdf1778537https://ri.ufs.br/jspui/bitstream/riufs/16325/2/ANNA_CLARA_RAMOS_S_SANTOS.pdf84a9b9296e24f12d6003d22d35c310c1MD52TEXTANNA_CLARA_RAMOS_S_SANTOS.pdf.txtANNA_CLARA_RAMOS_S_SANTOS.pdf.txtExtracted texttext/plain71429https://ri.ufs.br/jspui/bitstream/riufs/16325/3/ANNA_CLARA_RAMOS_S_SANTOS.pdf.txt97c17f4407bfb8370651beb1b8351d4bMD53THUMBNAILANNA_CLARA_RAMOS_S_SANTOS.pdf.jpgANNA_CLARA_RAMOS_S_SANTOS.pdf.jpgGenerated Thumbnailimage/jpeg1588https://ri.ufs.br/jspui/bitstream/riufs/16325/4/ANNA_CLARA_RAMOS_S_SANTOS.pdf.jpgf2c150d6aa19bcc397cea101dd6df5f1MD54riufs/163252022-09-21 10:57:14.775oai:ufs.br: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2022-09-21T13:57:14Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false
dc.title.pt_BR.fl_str_mv Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
title Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
spellingShingle Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
Santos, Anna Clara Ramos da Silva
COVID-19
Inquéritos epidemiológicos
Sergipe
Epidemiological inquiries
CIENCIAS DA SAUDE::FARMACIA
title_short Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
title_full Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
title_fullStr Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
title_full_unstemmed Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
title_sort Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
author Santos, Anna Clara Ramos da Silva
author_facet Santos, Anna Clara Ramos da Silva
author_role author
dc.contributor.author.fl_str_mv Santos, Anna Clara Ramos da Silva
dc.contributor.advisor1.fl_str_mv Araújo, Adriano Antunes de Souza
contributor_str_mv Araújo, Adriano Antunes de Souza
dc.subject.por.fl_str_mv COVID-19
Inquéritos epidemiológicos
Sergipe
topic COVID-19
Inquéritos epidemiológicos
Sergipe
Epidemiological inquiries
CIENCIAS DA SAUDE::FARMACIA
dc.subject.eng.fl_str_mv Epidemiological inquiries
dc.subject.cnpq.fl_str_mv CIENCIAS DA SAUDE::FARMACIA
description A new coronavirus from the Coronaviridae family was identified in December 2019 as a cause of complications in the pulmonary pathways in humans, SARS-Cov-2. On February 26, 2020, the first case of infection was confirmed in Brazil, and since then a real war has started to fight the pandemic. This work was the first populationbased seroprevalence study on SARS-CoV-2 infection carried out in Sergipe. In this study we investigated the seroprevalence of antibodies against severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) in the state of Sergipe, Northeastern Brazil, using rapid IgM − IgG antibody test and fluorescence immunoassay during the first wave of the disease. in Brazil from July to August 2020. In order to identify gender and age group with the greatest applicability of rapid tests and evaluate the number of asymptomatic and symptomatic people, as well as the most presented symptoms. Seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2– 11.3) for women and 7.9% (95% CI 6, 8–9.1) for men (p = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20– 59 years (9.3%; 95% CI 8.4-10.3) and ≥60 years (9.0%; 95% CI 7.5-10.8) (p = 0.517). The metropolitan region had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than inland municipalities (8.0%, 95% CI 7.2–8.9) (P <0.001). These findings highlight the importance of serosurveillance in estimating the true impact of the COVID-19 outbreak and thereby providing data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results can be useful as baseline data to track the progress of the COVID-19 outbreak as social restraint initiatives begin to be relaxed in Brazil.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-09-21T13:57:14Z
dc.date.available.fl_str_mv 2022-09-21T13:57:14Z
dc.date.issued.fl_str_mv 2022-02-28
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv SANTOS, Anna Clara Ramos da Silva. Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe. 2022. 51 f. Dissertação (Mestrado em Ciências Farmacêuticas) – Universidade Federal de Sergipe, São Cristóvão, 2022.
dc.identifier.uri.fl_str_mv http://ri.ufs.br/jspui/handle/riufs/16325
identifier_str_mv SANTOS, Anna Clara Ramos da Silva. Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe. 2022. 51 f. Dissertação (Mestrado em Ciências Farmacêuticas) – Universidade Federal de Sergipe, São Cristóvão, 2022.
url http://ri.ufs.br/jspui/handle/riufs/16325
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.program.fl_str_mv Pós-Graduação em Ciências Farmacêuticas
dc.publisher.initials.fl_str_mv Universidade Federal de Sergipe
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFS
instname:Universidade Federal de Sergipe (UFS)
instacron:UFS
instname_str Universidade Federal de Sergipe (UFS)
instacron_str UFS
institution UFS
reponame_str Repositório Institucional da UFS
collection Repositório Institucional da UFS
bitstream.url.fl_str_mv https://ri.ufs.br/jspui/bitstream/riufs/16325/1/license.txt
https://ri.ufs.br/jspui/bitstream/riufs/16325/2/ANNA_CLARA_RAMOS_S_SANTOS.pdf
https://ri.ufs.br/jspui/bitstream/riufs/16325/3/ANNA_CLARA_RAMOS_S_SANTOS.pdf.txt
https://ri.ufs.br/jspui/bitstream/riufs/16325/4/ANNA_CLARA_RAMOS_S_SANTOS.pdf.jpg
bitstream.checksum.fl_str_mv 098cbbf65c2c15e1fb2e49c5d306a44c
84a9b9296e24f12d6003d22d35c310c1
97c17f4407bfb8370651beb1b8351d4b
f2c150d6aa19bcc397cea101dd6df5f1
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)
repository.mail.fl_str_mv repositorio@academico.ufs.br
_version_ 1802110779041775616